Over the last several years, GLP-1 medications have been featured in headlines all over the world. From headlines about the impacts of the medication, to incredible weight loss outcomes for everyone from famous athletes to everyday people. More than that, we have learned that they appear to be powerful anti-inflammatory agents that help aid more than just the metabolism.
What is a GLP-1 Medication?
GLP-1 is a naturally occurring hormone in your body, produced primarily in the gut. These hormones play a key role in regulating your blood sugar, appetite, and digestion. GLP-1 receptor agonists, the drugs that mimic this hormone, were originally developed for type 2 diabetes. However, researchers quickly realized that the benefits of these medications surpassed expectations and the mere impact on diabetes patients.
Chronic low-grade inflammation is a common pathological mechanism underlying metabolic, cardiovascular, and neurodegenerative diseases and GLP-1 appears to target it directly.
A Body-Wide Anti-inflammatory Effect:
GLP-1 receptor agonists exert broad anti-inflammatory effects in multiple peripheral organs, including the central nervous system, lungs, cardiovascular system, liver, intestine, kidneys, and joints. One note that is particularly intriguing: only 20–60% of the improvement in inflammatory markers can be explained by weight or glucose changes, meaning the drugs appear to have direct anti-inflammatory properties independent of weight loss.
The Heart:
Studies show that Cardiovascular disease and inflammation are linked; inflamed arterial walls are a core driver of heart attacks and stroke. High-sensitivity C-reactive protein (CRP), an indicator of systemic inflammation, was significantly reduced in people with type 2 diabetes and cardiovascular disease treated with semaglutide.
A major 2025 study published in Nature Medicine, involving nearly a million people with diabetes followed for nearly a decade, found that those who took GLP-1 drugs had a 10–20% reduction in heart failure, cardiac arrest, lung failure, and pneumonia compared with those on other diabetes medications.
The Brain:
Neuroinflammation, which is defined as the inflammation of the brain tissue, is increasingly understood to be a driver of neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. GLP-1 is also produced in the brain itself, where it plays a critical role in neuroprotection and inflammation by activating GLP-1 receptor signaling pathways.
Ongoing phase III trials called EVOKE and EVOKE+ are currently testing oral semaglutide specifically in early Alzheimer’s patients, with results expected soon. It is quite an exciting frontier!
The Joints:
Outside of the obvious impacts of weight loss and the relief that it can have for joint pain, there are also direct benefits for the joint tissue itself. In a rheumatoid arthritis mouse experiment, liraglutide administration reduced synovial inflammation and decreased pro-inflammatory cytokine production, resulting in better outcomes for joint damage. Clinical trials are currently underway.
The Bottom Line:
While these drugs were initially invented for blood glucose and weight control, an increasing number of studies are finding additional benefits on the body. At a cellular level, GLP-1 antagonists work hard to reduce inflammation, likely impacting the heart, brain, and joints in a therapeutic way.
If you’re considering a GLP-1 medication, the conversation starts with your medical providers. But for anyone interested in the future of inflammation science, GLP-1 is absolutely worth keeping an eye on.
